KEAP1 and neoplasm: Series of co-occurring mutations in these genes (KRAS, LKB1, and KEAP1) associated with NRF2 overexpression drive tumor progression by causing and supporting metabolic shift and reprogramming [207] resulting in metastases and cis-platinum resistance [205].